Phenethyl Isothiocyanate Suppresses the Proinflammatory Cytokines in Human Glioblastoma Cells through the PI3K/Akt/NF-κB Signaling Pathway In Vitro

Sheng-Yao Hsu,1,2 Shih-Chieh Lee,3 Hsin-Chung Liu,4 Shu-Fen Peng,4,5 Fu-Shin Chueh,6 Tai-Jung Lu,4 Hsu-Tung Lee,7,8,9 and Yu-Cheng Chou10,11,12

1Department of Ophthalmology, An Nan Hospital, China Medical University, Tainan, Taiwan
2Department of Optometry, Chung Hwa University of Medical Technology, Tainan, Taiwan
3Department of Food Science and Biotechnology, Da-Yeh University, Daan, Changhua 515, Taiwan
4Department of Biological Science and Technology, China Medical University, Taichung 404, Taiwan
5Department of Medical Research, China Medical University Hospital, Taichung 404, Taiwan
6Department of Food Nutrition and Health Biotechnology, Asia University, Taichung 413, Taiwan
7Cancer Prevention and Control Center, Taichung Veterans General Hospital, Taichung 407, Taiwan
8Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan
9College of Medicine, National Chung Hsing University, Taichung 402, Taiwan
10Department of Neurosurgery, Neurological Institute, Taichung Veterans General Hospital, Taichung 407, Taiwan
11Department of Applied Chemistry, National Chi Nan University, Nantou 545, Taiwan
12Department of Neurological Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan

Correspondence should be addressed to Yu-Cheng Chou; chouycns@yahoo.com.tw

Received 1 August 2021; Revised 8 February 2022; Accepted 17 February 2022; Published 25 March 2022

Phenethyl isothiocyanate (PEITC), extracted from cruciferous vegetables, showed anticancer activity in many human cancer cells. Our previous studies disclosed the anticancer activity of PEITC in human glioblastoma multiforme (GBM) 8401 cells, including suppressing the cell proliferation, inducing apoptotic cell death, and suppressing cell migration and invasion. Furthermore, PEITC also inhibited the growth of xenograft tumors of human glioblastoma cells. We are the first to investigate PEITC effects on the receptor tyrosine kinase (RTK) signaling pathway and the effects of proinflammatory cytokines on glioblastoma. The cell viability was analyzed by flow cytometric assay. The protein levels and mRNA expressions of cytokines, including tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6), were determined by enzyme-linked immunosorbent assay (ELISA) reader and real-time polymerase chain reaction (PCR) analysis, respectively. Furthermore, nuclear factor-kappa B (NF-κB)- associated proteins were evaluated by western blotting. NF-κB expression and nuclear translocation were confirmed by confocal laser microscopy. NF-κB binding to the DNA was examined by electrophoretic mobility shift assay (EMSA). Our results indicated that PEITC decreased the cell viability and inhibited the protein levels and expressions of IL-1β, IL-6, and TNF-α genes at the transcriptional level in GBM 8401 cells. PEITC also altered the protein expressions of protein kinase B (Akt), extracellular signal-regulated kinase (ERK), and NF-κB signaling pathways. The inflammatory responses in human glioblastoma cells may be suppressed by PEITC through the phosphoinositide 3-kinase (PI3K)/Akt/NF-κB signaling pathway. Thus, PEITC may have the potential to be an anti-inflammatory agent for human glioblastoma in the future.
1. Introduction

The incidence rate of glioblastoma multiforme (GBM) was 2.9 times in the USA (2.48 per 100,000) and as many as that in Taiwan (0.85 per 100,000) [1]. Patients with GBM had the lowest survival rate in the histology of primary malignant brain and CNS tumors: the one-year survival rate was 37.5% in the USA and 50.3% in Taiwan, respectively. According to a hospital-based study from the National Cancer Database in the USA, even GBM patients treated at an academic medical center and the high-volume facility had the median overall survival of 13.3 months [2]. Current multimodality treatments cannot control this most common and aggressive primary brain malignancy well.

The complex pathogenesis in GBM involves receptor tyrosine kinase (RTK) signaling through two main downstream signaling pathways, Ras/mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) and Ras/phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) [3]. Besides, inhibition of the ERK/NF-κB signaling pathway can block GBM progression [4]. Cytokines including tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), pathogen-associated molecular patterns, ultraviolet and ionizing radiation, reactive oxygen species, growth factors, DNA damage, and oncogenic stress can trigger NF-κB activation pathways [5]. TNF-α is a proinflammatory cytokine with pleiotropy and biological effects [6]. However, the Akt pathway triggers critical immune and inflammatory responses in human embryonic kidney 293 cells [7]. It activates NF-κB by tumor necrosis factor (TNF). High levels of inflammatory cytokines such as IL-1β, IL-6, and IL-8 enhance cell proliferation, invasion, stemness, and angiogenesis [8]. Furthermore, the elevated inflammatory cytokine IL-6 can raise tumor progression and invasion in GBM, and high levels of IL-1β also activate GBM cells and promote IL-6 production [9].

Phenethyl isothiocyanate (PEITC), a component extracted from cruciferous vegetables, exhibits chemopreventive activity in diverse tumors. It has been investigated in small human clinical trials against various diseases from cancer to autism [10]. PEITC targets proteins that inhibit different cancer-promoting mechanisms, including cell proliferation, progression, and metastasis [11]. Our previous studies disclosed the in vitro effects of PEITC on human GBM 8401 cells, including the apoptosis induction [12], the reduction of migration and invasion through the inhibition of uPA, Rho A, and Ras, as well as the inhibition of matrix metalloproteinase gene expression [13], and the changes of the gene expressions and the levels of cell cycle regulation-associated proteins [14]. Furthermore, we also revealed that PEITC suppressed the in vivo growth of xenograft tumors of human GBM cells [15]. Literature reported that the pretreatment of PEITC promoted the sensitivity of temozolomide- (TMZ-) resistant glioblastoma cell lines and toward TMZ to inhibit the expression of O6-methylguanine-DNA methyltransferase (MGMT) through suppressing NF-κB activity to reverse the chemoresistance [16].

No reports reveal PEITC effects on RTK signaling pathways and immune-inflammatory responses of GBM in the available literature. In the present study, we first investigated the regulations among ERK, Akt-dependent pathways, NF-κB activity, and cytokine levels in GBM 8401 cells after PEITC treatment in vitro.

2. Materials and Methods

2.1. Chemicals and Reagents. PEITC, Tris-HCl, trypan blue, propidium iodide (PI), and dimethyl sulfoxide (DMSO) were obtained from Sigma Chemical Co. (St. Louis, MO, USA). RPMI-1640, fetal bovine serum (FBS), L-glutamine, penicillin-streptomycin, and trypsin-EDTA were purchased from Gibco BRL/Invitrogen (Carlsbad, CA, USA). IL-1β (ab214025), IL-6 (ab178013), and TNF-α (ab181421) were purchased from Abcam (Cambridgeshire, UK). Primary antibodies and secondary antibodies were obtained from Cell Signaling Technology (St. Louis, MO, USA). Polyvinylidene difluoride (PVDF) membrane was obtained from Millipore (Temecula, CA, USA). PEITC was dissolved in DMSO.

2.2. Cell Culture. Human brain glioblastoma multiforme (GBM) 8401 cell line was purchased from the Food Industry Research and Development Institute (Hsinchu, Taiwan). Cells were cultured in RPMI-1640 medium supplemented with 10% FBS, 2 mM L-glutamine, and 1% antibiotics (100 units/ml penicillin and 100 μg/ml streptomycin), grown at 37°C under a humidified 5% CO2 and 95% air at one atmosphere. The medium was changed every two days [17].

2.3. Cell Morphological Observation and Cell Viability Measurement. GBM 8401 cells at a density of 1 × 105 cells/well were plated in 12-well plates and were treated with PEITC at the final concentrations (0, 4, 8, and 12 μM) for 48 h. Cells from each well were monitored for morphological examination, and representative photographs were taken at ×200 magnification under an inverted microscope. To determine cell viability, cells from the individual well were trypsinized and collected by centrifuging at 1500 rpm for 5 min, washed twice with PBS, and added PI solution (5 μg/ml). Nonviable cells were stained with PI dye and displayed brighter fluorescence than the viable cells by flow cytometric analysis (FACSCalibur, Becton-Dickinson; San Jose, CA, USA) [18].

2.4. IL-1β, IL-6, and TNF-α Determination by Enzyme-Linked Immunosorbent Assay (ELISA) Reader. The GBM 8401 cells (2.5 × 105 cells) in RPMI-1640 medium containing 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 units/ml penicillin, and 100 μg/ml streptomycin with various concentrations of PEITC (0, 4, 8, and 12 μM) were placed on a 24-well culture plate for 48 h. At the end of incubation, cells were centrifuged and medium was collected for ELISA. In brief, 50 μl of medium was added to 50 μl of the antibody cocktail and was incubated for 1 hour at room temperature. Each well was washed with 1x wash buffer, and 100 μl of development solution was added to each well and incubated for 10 minutes in the dark. 100 μl of stop solution was added to well for ELISA Reader, set the OD at 450 nm as described previously [19].
2.5. Real-Time Polymerase Chain Reaction (RT-PCR). GBM 8401 cells (2.4 × 10^6 cells/dish) were plated to 10 cm dishes overnight and then exposed to 0 and 8 μM of PEITC for 24 h. Cells from the individual sample were collected, and the total RNA was isolated using the Qiagen RNeasy Mini Kit (Qiagen, Inc., Valencia, CA, USA) as described previously [20–22]. RNA samples were reverse-transcribed to cDNA at 42°C for 30 min using the High-Capacity cDNA Reverse Transcription Kit. A defined amount of cDNA was mixed with the Master Mix containing SYBR Green and 200 nM of primers shown in Table 1. Then, quantitative PCR was performed by 50°C for 2 min, 95°C for 10 min, and 40 cycles of 95°C for 15 sec and 60°C for 1 min using the Applied Biosystems 7300 Real-Time PCR System in triplicate. The fold change of gene expression was determined using the comparative 2^ΔΔCt method based on comparing with the level of GAPDH.

2.6. Western Blotting Assay. GBM 8401 cells (1 × 10^6 cells/dish) were plated in 10cm dishes and treated with 0 and 8 μM of PEITC for 0, 6, 24, and 48 h. After treatment, cells were collected and lysed in lystate buffer composed of 40 mM Tris-HCl (pH 7.4), 10 mM EDTA, 120 mM NaCl, 1 mM dithiothreitol, and 0.1% Nonide P-40. The protein concentration of each treatment was determined by using the Biorad Protein Assay Kit (Hercules, CA, USA) and then electrotransferred to PVDF membranes (Millipore, Temecula, CA, USA). The resultant blot was soaked in blocking buffer, 2.5% BSA in TBST (Tris-buffered saline containing Tween-20) for 1 h at room temperature. Then, the blots were probed with the primary antibodies for t-ERK1/2, p-ERK1/2Thr202/Tyr204, PI3K, p-Akt1/PKBαThr308, p-Akt1/PKBαSer473, Akt, p-p65Ser529, p-p65Ser276, p-p65Ser11, p-ILKα/βThr23, IKKα/β, p-1kBαSer32/Ser36, and β-actin (Cell Signaling Technology; Beverly, MA, USA) in blocking buffer at 4°C overnight. Immunoreactive proteins were reacted with horseradish peroxidase- (HRP-) conjugated secondary antibodies (Cell Signaling Technology; Beverly, MA, USA) and detected by chemiluminescence. The relative protein expression from each treatment was assessed by ImageJ software as described previously [23].

2.7. Observations of Confocal Laser Scanning Microscopy. GBM 8401 cells at a density of 1 × 10^5 cells/well were maintained on 18 mm coverslips and then treated with PEITC (0 and 8 μM) for 24 h. At the end of treatment, cells were fixed with 4% paraformaldehyde in PBS and permeabilized using 0.2% Triton-X 100 in PBS for 15 min. Subsequently, cells were washed with PBS and probed with an anti-p65 antibody (Novus Biologicals; Centennial, CO, USA) and then reacted with secondary antibodies conjugated with FITC (green fluorescence), and their nucleus was stained by PI (red fluorescence). All samples were observed and photographed under a Leica TCS SP8 Confocal Spectral Microscope, as described previously [24].

2.8. Electrophoretic Mobility Shift Assay (EMSA). GBM 8401 cells (5 × 10^5 cells/dish) were plated into 10cm dishes and were incubated with 0, 4, 8, and 12 μM of PEITC for 24 h. Cells were harvested for nuclear extracts by using the NE-PER Nuclear and Cytoplasmic Extraction Kit (Pierce, Rockford, Illinois, USA), and the protein concentrations for EMSA were determined with a LightShift Chemiluminescent EMSA Kit (Pierce) as described previously [22].

2.9. Statistical Analysis. All data were represented with the mean ± standard error from at least three independent experiments. One-way analysis of variance (ANOVA) with Newman-Keuls multicomparison test was used for the comparison between PEITC-treated and control groups. The difference between PEITC-treated and control was considered significant if p < 0.05.

3. Results

3.1. PEITC Decreased the Cell Viability of GBM 8401 Cells. GBM 8401 cells were treated with PEITC at different concentrations (0, 4, 8, and 12 μM) for 48 h before the cells were analyzed. The cell morphology was monitored, and the cytotoxicity of PEITC treatment was determined. PEITC induced morphological alternations of GBM 8401 cells based on cells that became smaller in size, shrinking, membrane blebbing, and floated on medium (Figure 1(a)). The total percentages of viable cells were analyzed by PI exclusion assay using flow cytometric assay, and results showed that PEITC diminished the number of viable GBM 8401 cells dose dependently (Figure 1(b)). After being exposed to more than 4 μM of PEITC, the total viable cells were significantly reduced in GBM 8401 cells. PEITC at 8 μM reduced cell viability to 52.4% in GBM 8401 cells, and more than 90% reduction of cells exposed to 12 μM of PEITC was observed after 48 h treatment. Thus, 8 μM of PEITC was selected for subsequent experiments.

3.2. PEITC Inhibited the Levels and mRNA Transcription of IL-1β, IL-6, and TNF-α Genes in GBM 8401 Cells. The effects of PEITC on the levels (proteins) and mRNA transcription of cytokine genes, including IL-1β, IL-6, and TNF-α, were
investigated by ELISA reader and real-time PCR analysis, respectively (Figures 2(a) and 2(b)). The levels (proteins) of IL-1β, IL-6, and TNF-α on GBM 8401 cells were of significant inhibition, and these effects were dose dependent (Figure 2(a)). Moreover, the mRNA expressions of IL-1β, IL-6, and TNF-α were indeed reduced 70%, 79.1%, and 84.5%, respectively, when GBM 8401 cells were exposed to 8 μM of PEITC for 24 h (****p < 0.001) compared to the control group (Figure 2(b)). Our data suggested that PEITC might regulate the expressions of IL-1β, IL-6, and TNF-α at the transcriptional level in GBM 8401 cells.

3.3. PEITC Altered Akt- and ERK-Associated Protein Expression in GBM 8401 Cells. MAPK and Akt signaling pathways involved in the secretion of TNF-α cytokine in GBM 8401 cells were investigated in this study. By western blotting analysis, PEITC at 8 μM decreased the protein levels of p-ERK1/2 Thr202/Tyr204 at 24 and 48 h treatment time dependently but did not change the protein levels of t-ERK1/2 significantly at 6, 24, and 48 h treatment (Figure 3(a)). Moreover, PEITC at 8 μM reduced the protein levels of PI3K, p-Aktα/PKBα Thr308, and Akt at 6, 24, and 48 h treatment in a time-dependent manner, respectively (Figure 3(b)). We also investigated the effects of PI3K inhibitor (LY 294002) pretreatment on GBM 8401 cells, and then, GBM 8401 cells were treated with PEITC for 48 h. Cells were harvested for western blotting for the expressions of PI3K, p-Aktα/PKBα Thr308, and p-p65 Ser276 in GBM 8401 cells (Figure 3(b)). Both cotreatments of PEITC and LY 94002 resulted in lower PI3K and p-PKBα Thr308 in GBM 8401 cells; however, there is no significant change in the levels of p-p65 Ser276.

3.4. PEITC Altered NF-κB Signaling Pathway-Associated Protein Levels, NF-κB Translocation, and NF-κB Activity in GBM 8401 Cells. The effects of PEITC on the TNF-α cytokine secretion were investigated for the involvement of the NF-κB signaling pathway. By western blotting analysis, PEITC at 8 μM decreased the protein levels of NF-κB (p-p65 Ser276) at 6, 24, and 48 h treatment and NF-κB (p-p65 Ser529) at 48 h (Figure 4(a)). PEITC at 8 μM decreased the protein levels of NF-κB (p65) at 24 and 48 h treatment in a time-dependent manner (Figure 4(a)). PEITC also reduced the protein levels of p-IκBα/β Thr23, IκBα/β, and p-IκBα Ser32/Ser36 by western blotting analysis in time-dependent manners (Figure 4(b)). Furthermore, PEITC at 8 μM abated the expression and nuclear translocation of NF-κB (p65) in GBM 8401 cells at 24 h, which were observed by confocal laser scanning microscopy (Figure 5).

3.5. PEITC Decreased the Binding of NF-κB p65 on DNA in GBM 8401 Cells. In order to further confirm the effects of PEITC on NF-κB p65 binding on DNA in GBM 8401 cells, cells were incubated with various concentrations of PEITC (0, 4, 8, and 12 μM) for 24 h and were collected and further assayed by using EMSA and results are shown in Figure 6. Results from Figure 6 show that NF-κB p65 binding on nuclear DNA was decreased at 25% and 58% at 8 and 12 μM of PEITC treatment, respectively.
4. Discussion

PEITC prevents the initiation of carcinogenesis and suppresses the progression of tumorigenesis [11]. The anticancer effects of PEITC on cell proliferation, apoptosis, angiogenesis, metastasis, autophagy, inflammation, and immunomodulation in different cancer models have been reported. PEITC reduced the cell viability of GBM 8401 cells in our previous experiments, including the studies of apoptosis, migration, and invasion [12, 13]. In the present study, PEITC changed the morphology of GBM 8401 cells (Figure 1(a)). PEITC reduced cell viability of GBM 8401 cells after 48 h treatment.
in a dose-dependent manner (Figure 1(b)), and the viability was decreased to 52.4% at 8 μM of PEITC treatment.

It is well documented that cytokines such as IL-1β, IL-6, and TNF-α were involved in inflammatory responses after host was exposed to environmental antigen. However, the excessive release of those inflammatory mediators may result in chronic inflammatory diseases if they are out of control. Thus, IL-1β or IL-6, TNF-α may be a target to control the inflammatory responses. Moreover, IL-1β and/or TNF-α have been shown to induce the expression of IL-6 in various tissues and cell types [25–29].

Therefore, we investigated whether or not PEITC affected the levels (protein) of IL-1β, IL-6, and TNF-α in GBM 8401 cells after treatment with or without PEITC at 0, 4, 8, and 12 μM for 24 h and were assayed by an ELISA reader. The results (Figure 2(a)) indicated that PEITC at 8 and 12 μM significantly inhibited the levels of IL-1β, IL-6, and TNF-α and higher concentrations of PEITC lead to higher inhibitions. The gene expression of IL-1β, IL-6, and TNF-α was inhibited by PEITC in a similar trend in GBM 8401 cells (Figure 2(b)).

RTK signaling regulates cell proliferation, survival, metastasis, and angiogenesis in GBM cells through the Ras/MAPK/ERK and Ras/PI3K/AKT pathway, two main downstream of RTK [3]. PEITC plays multiple biological functions in human cancer cells. PEITC inhibited the invasion and migration of human colon cancer HT29 cells by decreasing SOS-1, PKC, ERK1/2, and Rho A which led to the reduction of MMP-2 and MMP-9. PEITC also interfered with the expressions of Ras, FAK, and PI3K and suppressed GRB2, NF-κB, iNOS, and COX-2, which resulted in inhibiting cell proliferation in HT29 cells [30]. In the human leukemia xenograft animal model, PEITC induced tumor cell apoptosis and reduced tumor growth via downregulations of AKT, JNK, and Mcl-1 [31]. PEITC repressed protein and gene expressions concerning Toll-like receptor 3 (TLR3-) mediated IFN regulatory factor 3 (IRF3) signaling pathway in vitro and in vivo [32]. TLR3 upon dsRNA binding involves its specific adaptor Toll/IL-1R domain-containing adapter protein inducing IFN-β to enhance the signal resulting in NF-κB- or IRF3-mediated upregulation of proinflammatory and cytokine genes. PEITC also
diminished the phosphorylation of epidermal growth factor receptor (EGFR), PI3K (p85), 3-phosphoinositide-dependent protein kinase 1 (PDK1), Akt, phosphorylated IKK, and IkB to inactivate NF-κB in human oral squamous carcinoma cells (SAS cells) [33]. Besides, PEITC launches the MAPK signaling pathway through the elevated expression of phosphorylated p38, JNK, and ERK. In our study, PEITC decreased the protein levels of p-ERK1/2 Thr202/Tyr206, pERK1/2 Thr202/ Tyr204, PI3K, p-Akt1/PKBa Thr308, p-Akt1/PKBa Ser473, and Akt in time-dependent manners (Figure 3(a)). Both cotreatments of PEITC and LY 94002 decreased PI3K and p-Akt/ PKBa Thr308 in GBM 8401 cells (Figure 3(b)). PEITC changed the levels of Akt- and ERK-associated proteins in GBM 8401 cells and may modulate several critical cellular pathways involving cell proliferation, survival, migration, and angiogenesis.

NF-κB is involved in the early phases of the cell cycle and regulates cell growth, differentiation, immune, and inflammatory responses [34]. Activation of NF-κB enhances the initiation and progression of tumors through the mechanism of angiogenesis, metastasis, and reprogramming of metabolism [5]. A heterodimer of the p50 and p65 subunits is the most widely studied form of NF-κB. NF-κB in the cytoplasm is bound in an inactive complex with IkB, a natural biological inhibitor of NF-κB, in most cells [35]. IkBa, IkBβ, p105/IkBγ (precursor of p50), p100 (precursor of p52), and IkB belong to the IkB family [36]. IkB kinase complex results in the phosphorylation of IkBa at serines 32 and 36 or IkBβ at serines 19 and 23 [37]. The phosphorylation of IkBa and IkBβ target IkB for ubiquitin-dependent degradation through the 26S proteasome complex and resulted in the release and nuclear translocation of NF-κB [38]. NF-κB is highly active in glioblastoma, promoting cell aggressiveness [39] and inflammatory niche [40]. NF-κB activity was also associated with shorter survival in glioma patients [41]. Targeting the NF-κB-FAT1 axis might inhibit the important tumor-promoting pathway in glioblastoma because FAT1 and NF-κB independently enhance protumorigenic inflammation and upregulate the expression of HIF-1α/EMT/stemness in tumors [42]. PEITC revoked receptor activator of NF-κB ligand- (RANKL-) induced degradation of IkB-α, a suppressive partner of NF-κB in RAW264.7 macrophages, and prohibited the activation of ERK1/2 and p38 MAPK from decreasing RANKL-induced osteoclastogenesis [43].

The NF-κB signaling pathway plays a critical role in anticancer mechanism. Cellular migration and invasion, which were induced by DLL4, could be inhibited by either β-catenin or a p50 inhibitor in glioblastoma U87MG and U251 cells [44]. The migration and invasion of glioma cells are synergistically promoted by Notch activation-stimulated β-catenin and NF-κB signaling pathways. The suppression of NF-κB binding activity may implicate in the inhibition of MMP in GBM 8401 cells, and several critical metastasis-related proteins, such as p-EGFR Tyr1068, SOS-1, GRB2, Ras, p-AKT Ser473, and p-AKT Thr308, NF-κB-p65, Snail, E-cadherin, N-cadherin, NF-κB, MMP-2, and MMP-9, were decreased by tetrandrine from our previous study [45]. In this study, PEITC reduced the protein levels of p-ERK1/2 Thr202/Tyr204, PI3K, p-Akt1/PKBa Thr308, p-Akt1/PKBa Ser473, and Akt in time-dependent manners by western blotting analysis (Figure 3(a)). PEITC at 8 μM decreased the levels of NF-κB (p-p65 Ser276, p-p65 Ser529, and p65) in a time-dependent manner by western blotting analysis (Figure 4(a)). PEITC diminished the levels of p-IKKα/β Thr23, p-IKKα/β Ser273, and p-IκBα Ser32/Ser36 after 6, 24, and 48 h treatment (Figure 4(b)). PEITC at 8 μM also abated the expression and nuclear translocation of NF-κB (p65) in GBM 8401 cells at 48 h by confocal laser scanning microscopy (Figure 5). These results indicated that PEITC affected the NF-κB signaling pathway and may affect the aggressiveness of glioblastoma and the inflammatory microenvironment. In our previous study, demethoxycurcumin inhibited the motility, migration, and invasion of GBM 8401 cells via inhibition of PI3K/Akt and NF-κB signaling pathways [46]. PEITC reduced migration and invasion through the inhibition of uPA, Rho A, and Ras with inhibition of matrix metalloproteinase gene expression in GBM 8401 cells [13]. Taken together, PEITC may also suppress the migration and invasion of GBM 8401 cells through Akt, ERK, and NF-κB signaling pathways.

Furthermore, PEITC reversed the TMZ resistance of glioblastoma cells (U373-R, U87-R, and T98G cells) by suppressing MGMT via inhibiting the NF-κB activity [16]. Inhibition of the NF-κB activity increased the sensitivity of glioblastoma cells to alkylating agents such as TMZ in patients with acquired or induced chemoresistance. PEITC also inhibited cell growth in the U373-R grafted xenograft mouse model. In our study in A375.S2 human melanoma cancer cells in vitro, PEITC suppressed cell migration and invasion by affecting the MAPK signaling pathway [47]. p-AKT Ser473 levels were increased by PEITC at 1-2.5 μM at 24 h, but decreased at 48 h treatment. PEITC at 2.5 μM
decreased NF-κB binding of p65 to DNA in A375.S2 cells, but at 1-2 μM, it increased the binding. In the present study, PEITC at 8 μM decreased the protein levels of PI3K, p-Akt1/PKBα Thr308, p-Akt1/PKBα Ser473, and Akt at 6, 24, and 48 h treatment in a time-dependent manner in GBM 8401 cells, respectively (Figure 3(a)). PEITC at 8 μM decreased the protein levels of NF-κB (p-p65Ser276) at 6, 24, and 48 h treatment in a time-dependent manner, and NF-κB (p-p65 Ser529) at 48 h treatment, respectively (Figure 4(a)). PEITC at 8 μM decreased the protein levels of NF-κB (p65) at 24 and 48 h treatment in a time-dependent manner (Figure 4(a)). PEITC may have different effects on MAPK and NF-κB signaling pathways in the same cancer cells at different concentrations and treatment timing. Furthermore, results from EMSA indicated that PEITC at 4 and 8 μM significantly inhibited the binding of NF-κB p65 on DNA in GBM 8401 cells (Figure 6). Therefore, further studies of the directions of these signaling pathways in glioblastoma cells at different concentrations and treatment timing of PEITC are needed.

IL-1β, a major proinflammatory cytokine, launches various malignant processes by activating different cells to increase key molecules driving oncogenic events [8]. A high level of IL-1β was observed in glioblastoma cells (CCF3 and U87MG cells) [48] and human glioblastoma specimens [49]. The binding of IL-1β and the IL-1R leads to activating NF-κB and MAPK signaling pathways and cooperatively induces the expression of target genes cooperatively [50]. IL-1β-dependent activation of NF-κB, p38 MAPK, and JNKs pathways, however, increases VEGF and sphingosine kinase 1, subsequently enhancing migration, invasion, and angiogenesis, respectively [8, 51]. GBM cells regain self-renewal capacity after exposure to IL-1β [52]. Furthermore, IL-1β and TGF-β cooperated to elicit upregulation of stemness factor genes and augmented invasiveness and drug resistance, leading to tumor growth in vivo [53]. Therefore, targeting the production and activity of IL-1β might control the progression of glioblastoma.

The level of IL-6 mRNA was stabilized, and IL-6 biosynthesis was increased by the activation of several signaling pathways by proinflammatory cytokines IL-1β or TNF-α [54]. IL-6-mediated STAT3 activation enhanced cell migration and invasion in glioblastoma cells (U251, T98G, and U87MG) [55]. TNF and the associated receptor superfamily are important to the development of glioblastoma, and upregulation of TNF-α is influential to the progression of glioblastoma in U373 glioma cells [56]. Targeting TNF superfamily-related genes may be a potential therapeutic approach for GBM [57]. In our study, PEITC inhibited the
transcription of IL-1β, IL-6, and TNF-α genes in GBM 8401 cells (Figure 2(b)) and may control the progression of GBM through targeting IL-1β or affecting IL-6 on the regulation of signaling pathways by proinflammatory cytokines IL-1β or TNF-α. The detailed mechanism needs to be confirmed in in vivo studies in the future.

5. Conclusions
PEITC significantly reduced the levels of proinflammatory cytokines, such as TNF-α, IL-6, and IL-1β genes, in transcriptional levels and modulated ERK- and Akt-dependent and NF-κB signaling pathways in GBM 8401 cells. The possible signaling pathways regarding PEITC on GBM 8401 cells are summarized (Figure 7). PEITC may have anti-inflammatory effects on GBM, which can be a basis for further experiments to explore the immune regulation of PEITC on glioblastoma in vivo.

Data Availability
The datasets applied and analyzed in the present study are available from the corresponding author on reasonable request.

Conflicts of Interest
The authors declare no conflicts of interest in this work.

Acknowledgments
This work was supported by Taichung Veterans General Hospital/Da-Yeh University Joint Research Program (TCVGH-DYU1088301), and it also was supported by the grant (ANHRF104-14) of An Nan Hospital, China Medical University, Tainan, Taiwan.

References
[1] L. N. Chien, H. Gittleman, Q. T. Ostrom et al., "Comparative brain and central nervous system tumor incidence and survival between the United States and Taiwan based on population-based registry," Frontiers in Public Health, vol. 4, article 151, 2016.
[2] P. Zhu, X. L. Du, J.-J. Zhu, and Y. Esquenazi, "Improved survival of glioblastoma patients treated at academic and high-volume facilities: a hospital-based study from the National Cancer Database," Journal of Neurosurgery, vol. 132, no. 2, pp. 491–502, 2019.
[3] J. R. D. Pearson and T. Regad, "Targeting cellular pathways in glioblastoma multiforme," Signal Transduction and Targeted Therapy, vol. 2, no. 1, p. 17040, 2017.
[4] F. T. Hsu, I. T. Chiang, Y. C. Kuo et al., "Amentillavone effectively blocked the tumor progression of glioblastoma via suppression of ERK/NF-κB signaling pathway," The American Journal of Chinese Medicine, vol. 47, no. 4, pp. 913–931, 2019.
[5] Y. Xia, S. Shen, and I. M. Verma, "NF-κB, an active player in human cancers," Cancer Immunology Research, vol. 2, no. 9, pp. 823–830, 2014.
[6] B. B. Aggarwal, "Signalling pathways of the TNF superfamily: a double-edged sword," Nature Reviews. Immunology, vol. 3, no. 9, pp. 745–756, 2003.
[7] O. Nidai Ozes, L. D. Mayo, J. A. Gustin, S. R. Pfeffer, L. M. Pfeffer, and D. B. Donner, "NF-κB activation by tumour necrosis factor requires the Akt serine-threonine kinase," Nature, vol. 401, no. 6748, pp. 82–85, 1999.
[8] Y. T. Yeung, K. L. McDonald, T. Grewal, and L. Munoz, "Interleukins in glioblastoma pathophysiology: implications for therapy," British Journal of Pharmacology, vol. 168, no. 3, pp. 591–606, 2013.
[9] F. M. Gurgis, Y. T. Yeung, M. X. Tang et al., "The p38-MK2-HuR pathway potentiates EGFRvIII-IL-1β-driven IL-6 secretion in glioblastoma cells," Oncogene, vol. 34, no. 22, pp. 2934–2942, 2015.
[10] D. L. Paliyaguru, J. M. Yuan, T. W. Kensler, and J. W. Fahey, "Isothiocyanates: translating the power of plants to people," Molecular Nutrition & Food Research, vol. 62, no. 18, article e1700965, 2018.
[11] P. Gupta, S. E. Wright, S. H. Kim, and S. K. Srivastava, "Phenethyl isothiocyanate: a comprehensive review of anti-cancer mechanisms," Biochimica et Biophysica Acta, vol. 1846, no. 2, pp. 405–424, 2014.
[12] Y. C. Chou, M. Y. Chang, M. J. Wang et al., "PEITC induces apoptosis of human brain glioblastoma GBM8401 cells through the extrinsic- and intrinsic-signaling pathways," Neurochemistry International, vol. 81, pp. 32–40, 2015.
[13] Y. C. Chou, M. Y. Chang, M. J. Wang et al., "PEITC inhibits human brain glioblastoma GBM 8401 cell migration and invasion through the inhibition of uPA, Rho A, and Ras with inhibition of MMP-2, -7 and -9 gene expression," Oncology Reports, vol. s, no. 5, pp. 2489–2496, 2015.
[14] Y. C. Chou, M. Y. Chang, M. J. Wang et al., "Phenethyl isothiocyanate alters the gene expression and the levels of protein associated with cell cycle regulation in human glioblastoma GBM 8401 cells," Environmental Toxicology, vol. 32, no. 1, pp. 176–187, 2017.
[15] Y. C. Chou, M. Y. Chang, H. T. Lee et al., "Phenethyl isothiocyanate inhibits in vivo growth of xenograft tumors of human glioblastoma cells," Molecules, vol. 23, no. 9, p. 2305, 2018.
[16] Z. Guo, H. Wang, J. Wei, L. Han, and Z. Li, "Sequential treatment of phenethyl isothiocyanate increases sensitivity of temozolomide resistant glioblastoma cells by decreasing expression of MGMT via NF-κB pathway," American Journal of Translational Research, vol. 11, no. 2, pp. 696–708, 2019.
[17] D. Y. Wang, C. C. Yeh, J. H. Lee, C. F. Hung, and J. G. Chung, "Berberine inhibited arylamine N-acetyltransferase activity and gene expression and DNA adduct formation in human malignant astrocytoma (C9T/VGH) and brain glioblastoma multiforms (GBM 8401) cells," Neurochemical Research, vol. 27, no. 9, pp. 883–899, 2002.
[18] H. F. Lu, T. Y. Lai, T. C. Hsia et al., "Danthron induces DNA damage and inhibits DNA repair gene expressions in GBM 8401 human brain glioblastoma multiforms cells," Neurochemical Research, vol. 35, no. 7, pp. 1105–1110, 2010.
[19] N. Y. Tang, J. S. Yang, Y. H. Chang et al., "Effects of wogonin on the levels of cytokines and functions of leukocytes associated with NF-kappa B expression in Sprague-Dawley rats," In Vivo, vol. 20, no. 4, pp. 527–532, 2006.
[20] C. C. Lin, J. T. Chen, J. S. Yang et al., "Danthron inhibits the migration and invasion of human brain glioblastoma
multiforme cells through the inhibition of mRNA expression of focal adhesion kinase, Rho kinases-1 and metalloproteinase-9,” *Oncology Reports*, vol. 22, no. 5, pp. 1033–1037, 2009.

[21] H. J. Lin, C. C. Su, H. F. Lu et al., “Curcumin blocks migration and invasion of mouse-rat hybrid retina ganglion cells (N18) through the inhibition of MMP-2, -9, FAK, Rho A and Rock-1 gene expression,” *Oncology Reports*, vol. 23, no. 3, pp. 665–670, 2010.

[22] J. S. Yang, C. C. Wu, H. Z. Lee et al., “Suppression of the TNF-alpha level is mediated by Gan-Lu-Yin (traditional Chinese medicine) in human oral cancer cells through the NF-kappa B, AKT, and ERK-dependent pathways,” *Environmental Toxicology*, vol. 31, no. 10, pp. 1196–1205, 2016.

[23] Y. L. Shih, H. M. Chou, H. C. Chou et al., “Casticin impairs cell migration and invasion of mouse melanoma B16F10 cells via PI3K/AKT and NF-kB signaling pathways,” *Environmental Toxicology*, vol. 32, no. 9, pp. 2097–2112, 2017.

[24] Y. C. Hsiao, S. F. Peng, K. C. Lai et al., “Genistein induces apoptosis in vitro and has antitumor activity against human leukemia HL-60 cancer cell xenograft growth in vivo,” *Environmental Toxicology*, vol. 34, no. 4, pp. 443–456, 2019.

[25] H. Saito, C. Patterson, Z. Hu et al., “Expression and self-regulatory function of cardiac interleukin-6 during endotoxemia,” *American Journal of Physiology. Heart and Circulatory Physiology*, vol. 279, no. 5, pp. H2241–H2248, 2000.

[26] S. J. Webb, J. R. McPherson, K. Pahan, and S. Koka, “Regulation of TNF-alpha-induced IL-6 production in MG-63 human osteoblast-like cells,” *Journal of Dental Research*, vol. 81, no. 1, pp. 17–22, 2002.

[27] A. J. Ammit, A. L. Lazaar, C. Irani et al., “Tumor necrosis factor-alpha-induced secretion of RANTES and interleukin-6 from human airway smooth muscle cells: modulation by glucocorticoids and beta-agonists,” *American Journal of Respiratory Cell and Molecular Biology*, vol. 26, no. 4, pp. 465–474, 2002.

[28] H. Eda, B. L. Burnette, H. Shimada, H. R. Hope, and J. B. Monahan, “Interleukin-1β-induced interleukin-6 production in A549 cells is mediated by both phosphatidylinositol 3-kinase and interleukin-1 receptor-associated kinase-4,” *Cell Biology International*, vol. 35, no. 4, pp. 355–358, 2011.

[29] L. Flower, R. Gray, J. Pinkney, and V. Mohamed-Ali, “Stimulation of interleukin-6 release by interleukin-1β from isolated human adipocytes,” *Cytokine*, vol. 21, no. 1, pp. 32–37, 2003.

[30] K. C. Lai, S. C. Hsu, C. L. Kuo et al., “Phenethyl isothiocyanate inhibited tumor migration and invasion via suppressing multiple signal transduction pathways in human colon cancer HT29 cells,” *Journal of Agricultural and Food Chemistry*, vol. 58, no. 20, pp. 11148–11155, 2010.

[31] N. Gao, A. Budhraja, S. Cheng et al., “Phenethyl isothiocyanate exhibits antiepileptic activity in vitro and in vivo by inactivating of Akt and activation of JNK pathways,” *Cell Death & Disease*, vol. 2, no. 4, article e140, 2011.

[32] J. Zhu, A. Ghosh, E. M. Coyle et al., “Differential effects of phenethyl isothiocyanate and D,L-sulforaphane on TLR3 signaling,” *Journal of Immunology*, vol. 190, no. 8, pp. 4400–4407, 2013.

[33] H. J. Chen, C. M. Lin, C. Y. Lee et al., “Phenethyl isothiocyanate suppresses EGF-stimulated SAS human oral squamous carcinoma cell invasion by targeting EGF receptor signaling,” *International Journal of Oncology*, vol. 43, no. 2, pp. 629–637, 2013.

[34] D. C. Guttridge, C. Albanese, J. Y. Reuther, R. G. Pestell, and A. S. Baldwin, “NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1,” *Molecular and Cellular Biology*, vol. 19, no. 8, pp. 5785–5799, 1999.

[35] P. A. Baeuerle and D. Baltimore, “NF-κB: ten years after,” *Cell*, vol. 87, no. 1, pp. 13–20, 1996.

[36] S. T. Whiteside, J. C. Epinat, N. R. Rice, and A. Israel, “I kappa B epsilon, a novel member of the I kappa B family, controls RelA and cRel NF-kappa B activity,” *The EMBO Journal*, vol. 16, no. 6, pp. 1413–1426, 1997.

[37] E. Zandi, D. M. Rothwarf, M. Delhase, M. Hayakawa, and M. Karin, “The IkB kinase complex (IKK) contains two kinase subunits, IKKα and IKKβ, necessary for IkB phosphorylation and NF-κB activation,” *Cell*, vol. 91, no. 2, pp. 243–252, 1997.

[38] T. S. Finco and A. S. Baldwin, “Mechanistic aspects of NF-κB regulation: the emerging role of phosphorylation and proteolysis,” *Immunity*, vol. 3, no. 3, pp. 263–272, 1995.

[39] D. Friedmann-Morvinski, R. Narasimamurthy, Y. Xia, C. Mysikw, Y. Soda, and I. M. Verma, “Targeting NF-κB in glioblastoma: a therapeutic approach,” *Science Advances*, vol. 2, no. 1, article e1501292, 2016.

[40] C. Culver, A. Sundqvist, S. Mudie, A. Melvin, D. Xiromidas, and S. Rocha, “Mechanism of hypoxia-induced NF-κB,” *Molecular and Cellular Biology*, vol. 30, no. 20, pp. 4901–4921, 2010.

[41] M. Bredel, D. M. Scholtens, A. K. Yadav et al., “NFKBIA deletion in glioblastomas,” *New England Journal of Medicine*, vol. 364, no. 7, pp. 627–637, 2011.

[42] C. Srivastava, K. Irshad, Y. Gupta et al., “NFκB is a critical transcriptional regulator of atypical cadherin FAT1 in glioma,” *BMC Cancer*, vol. 20, no. 1, pp. 62, 2020.

[43] A. Murakami, M. Song, and H. Ohigashi, “Phenethyl isothiocyanate suppresses receptor activator of NF-kappaB ligand (RANKL)-induced osteoclastogenesis by blocking activation of ERK1/2 and p38 MAPK in RAW264.7 macrophages,” *BioFactors*, vol. 30, no. 1, pp. 1–11, 2007.

[44] X. Zhang, T. Chen, J. Zhang et al., “Notch1 promotes glioma cell migration and invasion by stimulating β-catenin and NF-κB signaling via AKT activation,” *Cancer Science*, vol. 103, no. 2, pp. 181–190, 2012.

[45] Y. W. Jiang, H. Y. Cheng, C. L. Kuo et al., “Tetrandrine inhibits human brain glioblastoma multiforme GBM 8401 cancer cell migration and invasion in vitro,” *Environmental Toxicology*, vol. 34, no. 4, pp. 364–374, 2019.

[46] R. Y. Su, C. C. Hsueh, C. Y. Chen et al., “Demethoxycurcumin suppresses proliferation, migration, and invasion of human brain glioblastoma multiforme GBM 8401 cells via PI3K/Akt pathway,” *Anticancer Research*, vol. 41, no. 4, pp. 1859–1870, 2021.

[47] Y. S. Ma, Y. T. Hsiao, J. J. Lin, C. L. Liao, C. C. Lin, and J. G. Chung, “Phenethyl isothiocyanate (PETIC) and benzyl isothiocyanate (BITC) inhibit human melanoma A375.S2 cell migration and invasion by affecting MAPK signaling pathway in vitro,” *Anticancer Research*, vol. 37, no. 11, pp. 6223–6234, 2017.

[48] T. Lu, L. Tian, Y. Han, M. Vogelbaum, and G. R. Stark, “Dose-dependent cross-talk between the transforming growth factor-beta and interleukin-1 signaling pathways,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 11, pp. 4365–4370, 2007.
V. Sharma, D. Dixit, N. Koul, V. S. Mehta, and E. Sen, "Ras regulates interleukin-1β-induced HIF-1α transcriptional activity in glioblastoma," *Journal of Molecular Medicine (Berlin, Germany)*, vol. 89, no. 2, pp. 123–136, 2011.

B. D. Griffin and P. N. Moynagh, "Persistent interleukin-1β signaling causes long term activation of NFκB in a promoter-specific manner in human glial cells," *The Journal of Biological Chemistry*, vol. 281, no. 15, pp. 10316–10326, 2006.

B. S. Paugh, L. Bryan, S. W. Paugh et al., "Interleukin-1 regulates the expression of sphingosine kinase 1 in glioblastoma cells*," *The Journal of Biological Chemistry*, vol. 284, no. 6, pp. 3408–3417, 2009.

J. Myung, B. K. Cho, Y. S. Kim, and S. H. Park, "Snail and Cox-2 expressions are associated with WHO tumor grade and survival rate of patients with gliomas," *Neuropathology*, vol. 30, no. 3, pp. 224–231, 2010.

L. Wang, Z. Liu, S. Balivada et al., "Interleukin-1β and transforming growth factor-β cooperate to induce neurosphere formation and increase tumorigenicity of adherent LN-229 glioma cells," *Stem Cell Research & Therapy*, vol. 3, no. 1, p. 5, 2012.

A. Spooren, P. Mestdagh, P. Rondou, K. Kolmus, G. Haegeman, and S. Gerlo, "IL-1β potently stabilizes IL-6 mRNA in human astrocytes," *Biochemical Pharmacology*, vol. 81, no. 8, pp. 1004–1015, 2011.

Q. Liu, G. Li, R. Li et al., "IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell lines," *Journal of Neuro-Oncology*, vol. 100, no. 2, pp. 165–176, 2010.

R. A. Kore and E. C. Abraham, "Inflammatory cytokines, interleukin-1 beta and tumor necrosis factor-alpha, upregulated in glioblastoma multiforme, raise the levels of CRYAB in exosomes secreted by U373 glioma cells," *Biochemical and Biophysical Research Communications*, vol. 453, no. 3, pp. 326–331, 2014.

H. Xie, C. Yuan, J. J. Li, Z. Y. Li, and W. C. Lu, "Potential molecular mechanism of TNF superfamily-related genes in glioblastoma multiforme based on transcriptome and epigenome," *Frontiers in Neurology*, vol. 12, article 576382, 2021.